Company Description: Kernal Bio is a biotech company developing mRNA 2.0 immunotherapies. Kernal mines translatome data to discover cell-specific sequence features and design mRNAs that are selectively translated in cancer cells and formulated with proprietary LNPs for extrahepatic delivery. Our lead program shows high efficacy and safety in preclinical tumor models resistant to checkpoint inhibitors. With roots at MIT, Harvard, Merck and BMS, Kernal’s management team has deep expertise in mRNA therapeutics with a 24 patent-wide IP portfolio. Based in Cambridge, MA, the company is backed by Hummingbird, Amgen, HBM, and Civilization Ventures.